Limits...
Modulation of inflammatory mediators in the trigeminal ganglion by botulinum neurotoxin type A: an organ culture study.

Edvinsson J, Warfvinge K, Edvinsson L - J Headache Pain (2015)

Bottom Line: Co-incubation with U0126 or BoNT-A retained the increased expression of SNAP-25, while it decreased the IL-1β immunoreactivity in neurons.It is clinically well recognized that treatment with corticosteroids will reduce the symptoms of chronic migraine; however this remedy is associated with long-term side effects.The results of the present work illustrate one way by which BoNT-A may modify these expressional alterations.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Lund University, Lund, Sweden, jacob.edvinsson@hotmail.com.

ABSTRACT

Background: Onabotulinumtoxin type A (BoNT-A) has been found to reduce pain in chronic migraine. The aim of the present study was to ask if BoNT-A can interact directly on sensory mechanisms in the trigeminal ganglion (TG) using an organ culture method.

Methods: To induce inflammation, rat TGs were incubated for 24 hrs with either the mitogen MEK1/2 inhibitor U0126, BoNT-A or NaCl. After this the TGs were prepared for immunohistochemistry. Sections of the TG were then incubated with primary antibodies against CGRP (neuronal transmitter), iNOS (inflammatory marker), IL-1β (Interleukin 1β), SNAP-25 (synaptic vesicle docking protein) or SV2-A (Botulinum toxin receptor element).

Results: We report that CGRP, iNOS, IL-1β, SNAP-25 and SV2-A were observed in fresh TG with a differential distribution. Interestingly, NaCl organ culture of the TG resulted in enhanced expression of CGRP and SNAP-25 in neurons and iNOS in SGCs. Co-incubation with U0126 or BoNT-A retained the increased expression of SNAP-25, while it decreased the IL-1β immunoreactivity in neurons. The iNOS expression in SGCs returned to levels observed in fresh specimens. Moreover, we observed no alteration SV2-A expression in SGCs. Thus, the overall picture is that both U0126 and BoNT-A have the ability to modify the expression of certain molecules in the TG.

Conclusion: We hypothesize that chronic migraine might be associated with some degree of inflammation in the TG that could involve both neurons and SGCs. It is clinically well recognized that treatment with corticosteroids will reduce the symptoms of chronic migraine; however this remedy is associated with long-term side effects. Understanding the mechanisms involved in the expressional alterations may suggest novel ways to modify the changes and indicate novel therapeutics. The results of the present work illustrate one way by which BoNT-A may modify these expressional alterations.

No MeSH data available.


Related in: MedlinePlus

Schematic drawings. The drawing demonstrates the major immunohistochemical findings in neurons and SGCs. CGRP, IL1β and SNAP-25 were mainly found in the neurons, and iNOS and SV2-A in the SGCs. Arrows illustrate increase and decrease, respectively.
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4526514&req=5

Fig7: Schematic drawings. The drawing demonstrates the major immunohistochemical findings in neurons and SGCs. CGRP, IL1β and SNAP-25 were mainly found in the neurons, and iNOS and SV2-A in the SGCs. Arrows illustrate increase and decrease, respectively.

Mentions: Major findings are illustrated schematically in Fig. 7.Fig. 7


Modulation of inflammatory mediators in the trigeminal ganglion by botulinum neurotoxin type A: an organ culture study.

Edvinsson J, Warfvinge K, Edvinsson L - J Headache Pain (2015)

Schematic drawings. The drawing demonstrates the major immunohistochemical findings in neurons and SGCs. CGRP, IL1β and SNAP-25 were mainly found in the neurons, and iNOS and SV2-A in the SGCs. Arrows illustrate increase and decrease, respectively.
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4526514&req=5

Fig7: Schematic drawings. The drawing demonstrates the major immunohistochemical findings in neurons and SGCs. CGRP, IL1β and SNAP-25 were mainly found in the neurons, and iNOS and SV2-A in the SGCs. Arrows illustrate increase and decrease, respectively.
Mentions: Major findings are illustrated schematically in Fig. 7.Fig. 7

Bottom Line: Co-incubation with U0126 or BoNT-A retained the increased expression of SNAP-25, while it decreased the IL-1β immunoreactivity in neurons.It is clinically well recognized that treatment with corticosteroids will reduce the symptoms of chronic migraine; however this remedy is associated with long-term side effects.The results of the present work illustrate one way by which BoNT-A may modify these expressional alterations.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Lund University, Lund, Sweden, jacob.edvinsson@hotmail.com.

ABSTRACT

Background: Onabotulinumtoxin type A (BoNT-A) has been found to reduce pain in chronic migraine. The aim of the present study was to ask if BoNT-A can interact directly on sensory mechanisms in the trigeminal ganglion (TG) using an organ culture method.

Methods: To induce inflammation, rat TGs were incubated for 24 hrs with either the mitogen MEK1/2 inhibitor U0126, BoNT-A or NaCl. After this the TGs were prepared for immunohistochemistry. Sections of the TG were then incubated with primary antibodies against CGRP (neuronal transmitter), iNOS (inflammatory marker), IL-1β (Interleukin 1β), SNAP-25 (synaptic vesicle docking protein) or SV2-A (Botulinum toxin receptor element).

Results: We report that CGRP, iNOS, IL-1β, SNAP-25 and SV2-A were observed in fresh TG with a differential distribution. Interestingly, NaCl organ culture of the TG resulted in enhanced expression of CGRP and SNAP-25 in neurons and iNOS in SGCs. Co-incubation with U0126 or BoNT-A retained the increased expression of SNAP-25, while it decreased the IL-1β immunoreactivity in neurons. The iNOS expression in SGCs returned to levels observed in fresh specimens. Moreover, we observed no alteration SV2-A expression in SGCs. Thus, the overall picture is that both U0126 and BoNT-A have the ability to modify the expression of certain molecules in the TG.

Conclusion: We hypothesize that chronic migraine might be associated with some degree of inflammation in the TG that could involve both neurons and SGCs. It is clinically well recognized that treatment with corticosteroids will reduce the symptoms of chronic migraine; however this remedy is associated with long-term side effects. Understanding the mechanisms involved in the expressional alterations may suggest novel ways to modify the changes and indicate novel therapeutics. The results of the present work illustrate one way by which BoNT-A may modify these expressional alterations.

No MeSH data available.


Related in: MedlinePlus